Indometacin farnesil
Jump to navigation
Jump to search
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | To indometacin |
Elimination half-life | 1.5 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.242.585 |
Chemical and physical data | |
Formula | C34H40ClNO4 |
Molar mass | 562.15 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.
External links
- Infree (indometacin farnesil capsules) Full Prescribing Information Archived 2010-12-03 at the Wayback Machine from Eisai Co.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes which contain changes to watched fields
- Webarchive template wayback links
- Benzamides
- Chloroarenes
- Indoles
- Nonsteroidal anti-inflammatory drugs
- Prodrugs
- Sesquiterpenes
- All stub articles
- Musculoskeletal system drug stubs